SCHEMBL9745072

SCHEMBL9745072

CC(C)c1ccc2c(c1)CCC1C(C(C)N)CCCC21C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 4/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ TSHR P16473 2/20 0.57
▸ CYP2D6 P10635 2/20 0.57
▸ CYP2C19 P33261 2/20 0.57
▸ PDK1 Q15118 1/20 0.57
▸ PDK2 Q15119 1/20 0.57
▸ PDK3 Q15120 1/20 0.57
▸ PDK4 Q16654 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ MAPK1 P28482 2/20 0.56
▸ TP53 P04637 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ LMNA P02545 1/20 0.55
▸ KARS1 Q15046 4/20 0.54
▸ RXRA P19793 1/20 0.53
▸ CCNE1 P24864 1/20 0.53
▸ CDK2 P24941 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20866213 0.84 CYP3A4 (0.57) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL19018793 0.84 CYP3A4 (0.57) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL19696488 0.81 KARS1 (0.54) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL6319704 0.81 KARS1 (0.56) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL19696490 0.80 KARS1 (0.53) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL18663759 0.78 CYP3A4 (0.54) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL9872931 0.77 CYP3A4 (0.48) CYP3A4MEN1KMT2ATSHRCYP2D6
Hydrochloric Acid SCHEMBL9871425 0.77 CYP3A4 (0.49) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL20866406 0.75 CYP3A4 (0.72) CYP3A4MEN1KMT2ATSHRCYP2D6
SCHEMBL15899658 0.74 CYP3A4 (0.72) CYP3A4MEN1KMT2ATSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9410074-B2 Compositions and methods for inhibiting naphthenate solids formation from liquid hydrocarbons M-I L.L.C. (US) 2016-08-09 — — US claimed
EP-2504407-B1 COMPOSITIONS AND METHODS FOR INHIBITING NAPHTHENATE SOLIDS FORMATION FROM LIQUID HYDROCARBONS M I AUSTRALIA PTY LTD (AU) 2015-03-25 — — EP claimed
US-20120310022-A1 Compositions And Methods For Inhibiting Naphthenate Solids Formation From Liquid Hydrocarbons M-I L. L. C. 2012-12-06 — — US claimed
US-9410074-B2 Compositions and methods for inhibiting naphthenate solids formation from liquid hydrocarbons M-I L.L.C. (US) 2016-08-09 — — US disclosed
EP-2504407-B1 COMPOSITIONS AND METHODS FOR INHIBITING NAPHTHENATE SOLIDS FORMATION FROM LIQUID HYDROCARBONS M I AUSTRALIA PTY LTD (AU) 2015-03-25 — — EP disclosed
US-20120310022-A1 Compositions And Methods For Inhibiting Naphthenate Solids Formation From Liquid Hydrocarbons M-I L. L. C. 2012-12-06 — — US disclosed
US-5153069-A For pigments Canestri, Giuseppe (IT) 1992-10-06 — — US disclosed
EP-0189385-B1 POLYESTERAMIDE DISPERSING AGENT Canestri, Giuseppe, Dr. (IT) 1991-05-02 — — EP disclosed
US-4999132-A For organic pigments, inks, paints BERGVIK KEMI AB (SE) 1991-03-12 — — US disclosed
EP-0189385-A2 Polyesteramide dispersing agent Canestri, Giuseppe, Dr. (IT) 1986-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120310022-A1 Compositions And Methods For Inhibiting Naphthenate Solids Formation From Liquid Hydrocarbons NR4A1, NR4A2, NR0B1 CYP3A4 54/4885MEN1 1819/4885KMT2A 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback